The following statement is attributable to:
Patrice Harris, MD, MA
Chair, AMA Opioid Task Force
AMA Immediate Past President

"The FDA recognized that the drug overdose epidemic is ever-changing, and government regulators must be agile to ensure that patients at risk of an opioid-related overdose have effective medication to help save their lives. By approving a higher dose of naloxone hydrochloride nasal spray product to treat opioid overdose, the FDA is making sure the overdose-reversing drug is potent enough to counteract the increasingly lethal and illicitly manufactured fentanyl and fentanyl analogs. Now, we must make sure that the new version of naloxone is placed on the lowest cost-sharing tier with low or no cost-sharing and also available in pharmacies.

“Communities are looking for tools to respond to the epidemic of drug overdoses, and the FDA action today adds a powerful one."

Media Contact:

Jack Deutsch

ph: (202) 789-7442

[email protected]

About the American Medical Association

The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care.  The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.

More about:
Featured Stories